Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Combination Treatment of Rituximab and Therapeutic Vaccines Affords Superior Tumor Suppression and Relapse Prevention for Non‐Hodgkin Lymphoma

Advanced Materials(2025)10.1002/adma.202502372Source: DataRank Database

Combination Treatment of Rituximab and Therapeutic Vaccines Affords Superior Tumor Suppression and Relapse Prevention for Non‐Hodgkin Lymphoma is a research paper published in Advanced Materials (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.40)OA: greenTopics (71)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Jimin Guo ORCID,Zheng Cao ORCID,Shilin Chen ORCID,E Kimura,Xiyao Li ORCID

Live enrichment

PubMed:40214308 PMC:PMC12227277 OpenAlex:https://openalex.org/W4409363006

NCATS NIH HHS

Grant: UL1 TR001881

NIAID NIH HHS

Grant: P30 AI028697

NCI NIH HHS

Grant: R01 CA253215

National Institutes of Health

Grant: 5R01CA253215-03

Targeting delivery of mAbs to CNS metastases

National Institutes of Health

Grant: 3UL1TR001881-01S2

UCLA Clinical Translational Science Institute

National Institutes of Health

Grant: 5P30AI028697-26

Biostatistics Core

FWCI

0.40

Citation Percentile

0.6%

Citation Trend

2026

greenLicense: Wiley Online Library User Agreement

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12227277

publisherhttps://advanced.onlinelibrary.wiley.com/doi/pdf/10.1002/adma.202502372

publisherhttps://advanced.onlinelibrary.wiley.com/doi/full-xml/10.1002/adma.202502372

journalhttps://doi.org/10.1002/adma.202502372

Fields of Study

Immunotherapy and Immune ResponsesImmune Cell Function and InteractionCAR-T cell therapy research0302 clinical medicine03 medical and health sciences

MeSH Terms

RituximabAnimalsHumansLymphoma, Non-HodgkinNeoplasm Recurrence, LocalCancer VaccinesCell Line, TumorMice

Keywords

RituximabLymphomaImmunotherapyMedicineMonoclonal antibodyRadioimmunotherapyOncologyImmunologyNon-Hodgkin's lymphomaMalignancyCancer researchInternal medicineAntibodyImmune systemTherapeutic Cancer VaccinesNon‐hodgkin LymphomaSynergy TherapyBlt Humanized Mouse ModelPrevention (rcdc)51 Physical sciences (for-2020)Mice34 Chemical sciences (for-2020)Animals (mesh)Lymphatic Research (rcdc)Immunization (rcdc)Cancer (rcdc)Humans (mesh)3 Good Health and Well Being (sdg)Lymphoma (rcdc)non-Hodgkin lymphomaLymphoma, Non-Hodgkin03 Chemical Sciences (for)Mice (mesh)Vaccine Related (rcdc)09 Engineering (for)Non-Hodgkin (mesh)Tumor (mesh)Biotechnology (rcdc)Cancer VaccinesCell LineRare Diseases (rcdc)5.1 Pharmaceuticals (hrcs-rac)Cell Line, TumorNanoscience & Nanotechnology (science-metrix)AnimalsHumansCancer Vaccines (mesh)Hematology (rcdc)02 Physical Sciences (for)6.1 Pharmaceuticals (hrcs-rac)Immunotherapy (rcdc)Cancer (hrcs-hc)40 Engineering (for-2020)Neoplasm RecurrenceOrphan Drug (rcdc)Local (mesh)Rituximab (mesh)Neoplasm Recurrence, Local

Sustainable Development Goals

SDG 0: Good health and well-being